These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 24522402)

  • 41. Population pharmacokinetic analysis of patritumab, a HER3 inhibitor, in subjects with advanced non-small cell lung cancer (NSCLC) or solid tumors.
    Yoshiba S; Jansen M; Matsushima N; Chen S; Mendell J
    Cancer Chemother Pharmacol; 2016 May; 77(5):987-96. PubMed ID: 27017616
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Diarrhea associated with afatinib: an oral ErbB family blocker.
    Yang JC; Reguart N; Barinoff J; Köhler J; Uttenreuther-Fischer M; Stammberger U; O'Brien D; Wolf J; Cohen EE
    Expert Rev Anticancer Ther; 2013 Jun; 13(6):729-36. PubMed ID: 23506556
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment.
    Schnell D; Buschke S; Fuchs H; Gansser D; Goeldner RG; Uttenreuther-Fischer M; Stopfer P; Wind S; Petersen-Sylla M; Halabi A; Koenen R
    Cancer Chemother Pharmacol; 2014 Aug; 74(2):267-75. PubMed ID: 24906422
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors.
    Gordon MS; Mendelson DS; Gross M; Uttenreuther-Fischer M; Ould-Kaci M; Zhao Y; Stopfer P; Agus DB
    Invest New Drugs; 2013 Apr; 31(2):409-16. PubMed ID: 23242861
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Development of population pharmacokinetics model of icotinib with non-linear absorption characters in healthy Chinese volunteers to assess the CYP2C19 polymorphism and food-intake effect.
    Hu P; Chen J; Liu D; Zheng X; Zhao Q; Jiang J
    Eur J Clin Pharmacol; 2015 Jul; 71(7):843-50. PubMed ID: 25995169
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Population Pharmacokinetic and Covariate Analysis of Apatinib, an Oral Tyrosine Kinase Inhibitor, in Healthy Volunteers and Patients with Solid Tumors.
    Yu M; Gao Z; Dai X; Gong H; Zhang L; Chen X; Zhong DF; Sy SK
    Clin Pharmacokinet; 2017 Jan; 56(1):65-76. PubMed ID: 27379402
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Influence of Renal Impairment on the Pharmacokinetics of Afatinib: An Open-Label, Single-Dose Study.
    Wiebe S; Schnell D; Külzer R; Gansser D; Weber A; Wallenstein G; Halabi A; Conrad A; Wind S
    Eur J Drug Metab Pharmacokinet; 2017 Jun; 42(3):461-469. PubMed ID: 27436099
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Afatinib Activity in Platinum-Refractory Metastatic Urothelial Carcinoma in Patients With ERBB Alterations.
    Choudhury NJ; Campanile A; Antic T; Yap KL; Fitzpatrick CA; Wade JL; Karrison T; Stadler WM; Nakamura Y; O'Donnell PH
    J Clin Oncol; 2016 Jun; 34(18):2165-71. PubMed ID: 27044931
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer.
    Bruno R; Washington CB; Lu JF; Lieberman G; Banken L; Klein P
    Cancer Chemother Pharmacol; 2005 Oct; 56(4):361-9. PubMed ID: 15868146
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Population pharmacokinetic analysis from phase I and phase II studies of the humanized monovalent antibody, onartuzumab (MetMAb), in patients with advanced solid tumors.
    Xin Y; Jin D; Eppler S; Damico-Beyer LA; Joshi A; Davis JD; Kaur S; Nijem I; Bothos J; Peterson A; Patel P; Bai S
    J Clin Pharmacol; 2013 Nov; 53(11):1103-11. PubMed ID: 23922054
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Population pharmacokinetics of sonidegib (LDE225), an oral inhibitor of hedgehog pathway signaling, in healthy subjects and in patients with advanced solid tumors.
    Goel V; Hurh E; Stein A; Nedelman J; Zhou J; Chiparus O; Huang PH; Gogov S; Sellami D
    Cancer Chemother Pharmacol; 2016 Apr; 77(4):745-55. PubMed ID: 26898300
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Population pharmacokinetic analysis of ten phase II clinical trials of pemetrexed in cancer patients.
    Latz JE; Chaudhary A; Ghosh A; Johnson RD
    Cancer Chemother Pharmacol; 2006 Apr; 57(4):401-11. PubMed ID: 16322991
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Population pharmacokinetic meta-analysis of trabectedin (ET-743, Yondelis) in cancer patients.
    Perez-Ruixo JJ; Zannikos P; Hirankarn S; Stuyckens K; Ludwig EA; Soto-Matos A; Lopez-Lazaro L; Owen JS
    Clin Pharmacokinet; 2007; 46(10):867-84. PubMed ID: 17854236
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Phase II study of afatinib, an irreversible ErbB family blocker, in EGFR FISH-positive non-small-cell lung cancer.
    Cappuzzo F; Finocchiaro G; Grossi F; Bidoli P; Favaretto A; Marchetti A; Valente ML; Cseh A; Clementi L; Massey D; Santoro A
    J Thorac Oncol; 2015 Apr; 10(4):665-72. PubMed ID: 25514804
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A neoadjuvant, randomized, open-label phase II trial of afatinib versus trastuzumab versus lapatinib in patients with locally advanced HER2-positive breast cancer.
    Rimawi MF; Aleixo SB; Rozas AA; Nunes de Matos Neto J; Caleffi M; Figueira AC; Souza SC; Reiriz AB; Gutierrez C; Arantes H; Uttenreuther-Fischer MM; Solca F; Osborne CK
    Clin Breast Cancer; 2015 Apr; 15(2):101-9. PubMed ID: 25537159
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours.
    Eskens FA; Mom CH; Planting AS; Gietema JA; Amelsberg A; Huisman H; van Doorn L; Burger H; Stopfer P; Verweij J; de Vries EG
    Br J Cancer; 2008 Jan; 98(1):80-5. PubMed ID: 18026190
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Population pharmacokinetics of losmapimod in healthy subjects and patients with rheumatoid arthritis and chronic obstructive pulmonary diseases.
    Yang S; Lukey P; Beerahee M; Hoke F
    Clin Pharmacokinet; 2013 Mar; 52(3):187-98. PubMed ID: 23254770
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacokinetic drug interactions of afatinib with rifampicin and ritonavir.
    Wind S; Giessmann T; Jungnik A; Brand T; Marzin K; Bertulis J; Hocke J; Gansser D; Stopfer P
    Clin Drug Investig; 2014 Mar; 34(3):173-82. PubMed ID: 24399452
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Population pharmacokinetics of vactosertib, a new TGF-β receptor type Ι inhibitor, in patients with advanced solid tumors.
    Jung SY; Yug JS; Clarke JM; Bauer TM; Keedy VL; Hwang S; Kim SJ; Chung EK; Lee JI
    Cancer Chemother Pharmacol; 2020 Jan; 85(1):173-183. PubMed ID: 31673825
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Population pharmacokinetic and pharmacodynamic analysis of bosutinib.
    Hsyu PH; Mould DR; Abbas R; Amantea M
    Drug Metab Pharmacokinet; 2014; 29(6):441-8. PubMed ID: 24919837
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.